SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Manuela C. Caciula, Michael Horvat, Phillip D. Tomporowski, Joe Nocera, The effects of exercise frequency on executive function in individuals with Parkinson's disease, Mental Health and Physical Activity, 2016, 10, 18

    CrossRef

  2. 2
    Meyler's Side Effects of Drugs, 2016,

    CrossRef

  3. 3
    F.I. Tarazi, Z.T. Sahli, M. Wolny, S.A. Mousa, Emerging therapies for Parkinson's disease: From bench to bedside, Pharmacology & Therapeutics, 2014, 144, 2, 123

    CrossRef

  4. 4
    Mark Nuijten, Marja Pronk, Financial Valuation Algorithm for the Assessment of the Future Sales of a New, Innovative Medicinal Product, The Journal of Private Equity, 2014, 17, 3, 35

    CrossRef

  5. 5
    Alfonso Fasano, Francesco Bove, Maurizio Gabrielli, Enzo Ragazzoni, Serena Fortuna, Annalisa Tortora, Maria Assunta Zocco, Stefano Marconi, Antonio Gasbarrini, Anna Rita Bentivoglio, Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth, Clinical Neuropharmacology, 2014, 37, 4, 91

    CrossRef

  6. 6
    Karoline Wenzel, Carl Nikolaus Homann, Giovanni Fabbrini, Carlo Colosimo, The role of subcutaneous infusion of apomorphine in Parkinson’s disease, Expert Review of Neurotherapeutics, 2014, 14, 7, 833

    CrossRef

  7. 7
    Alfonso Fasano, Francesco Bove, Maurizio Gabrielli, Martina Petracca, Maria Assunta Zocco, Enzo Ragazzoni, Federico Barbaro, Carla Piano, Serena Fortuna, Annalisa Tortora, Raffaella Giacopo, Mariachiara Campanale, Giovanni Gigante, Ernesto Cristiano Lauritano, Pierluigi Navarra, Stefano Marconi, Antonio Gasbarrini, Anna Rita Bentivoglio, The role of small intestinal bacterial overgrowth in Parkinson's disease, Movement Disorders, 2013, 28, 9
  8. 8
    Meir Plotnik, Yaacov Dagan, Tanya Gurevich, Nir Giladi, Jeffrey M. Hausdorff, Effects of cognitive function on gait and dual tasking abilities in patients with Parkinson’s disease suffering from motor response fluctuations, Experimental Brain Research, 2011, 208, 2, 169

    CrossRef

  9. 9
    Jennifer M. King, Gladson Muthian, Veronica Mackey, Marquitta Smith, Clivel Charlton, L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease, Life Sciences, 2011, 89, 17-18, 638

    CrossRef

  10. 10
    Winnie Jeng, Annmarie Ramkissoon, Peter G. Wells, Reduced DNA oxidation in aged prostaglandin H synthase-1 knockout mice, Free Radical Biology and Medicine, 2011, 50, 4, 550

    CrossRef

  11. 11
    Mario Zappia, Carlo Colosimo, Werner Poewe, Levodopa: back to the future, Journal of Neurology, 2010, 257, S2, 247

    CrossRef

  12. 12
    Mark A. Stacy, Harald Murck, Kurt Kroenke, Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1, 57

    CrossRef

  13. 13
    Rajesh Pahwa, Kelly E. Lyons, Levodopa-related wearing-off in Parkinson's disease: identification and management, Current Medical Research and Opinion, 2009, 25, 4, 841

    CrossRef

  14. 14
    Meyler's Side Effects of Psychiatric Drugs, 2009,

    CrossRef

  15. 15
    P.A. Silburn, G.D. Mellick, B.I. Vieira, G. Danta, R.S. Boyle, L. Herawati, Utility of a patient survey in identifying fluctuations in early stage Parkinson’s disease, Journal of Clinical Neuroscience, 2008, 15, 11, 1235

    CrossRef

  16. 16
    V. Pursiainen, J. T. Korpelainen, T. H. Haapaniemi, K. A. Sotaniemi, V. V. Myllylä, Blood pressure and heart rate in parkinsonian patients with and without wearing-off, European Journal of Neurology, 2007, 14, 4
  17. 17
    Angelo Antonini, Ioannis U. Isaias, Margherita Canesi, Maurizio Zibetti, Francesca Mancini, Luigi Manfredi, Marco Dal Fante, Leonardo Lopiano, Gianni Pezzoli, Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome, Movement Disorders, 2007, 22, 8
  18. 18
    Carlo Colosimo, Giovanni Fabbrini, Alfredo Berardelli, Drug Insight: new drugs in development for Parkinson's disease, Nature Clinical Practice Neurology, 2006, 2, 11, 600

    CrossRef

  19. 19
    Roberto Vetrugno, Manuela Contin, Agostino Baruzzi, Federica Provini, Giuseppe Plazzi, Pasquale Montagna, Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome, Movement Disorders, 2006, 21, 2
  20. 20
    Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2006,

    CrossRef

  21. 21
    Mark Stacy, Annette Bowron, Mark Guttman, Robert Hauser, Kim Hughes, Jan Petter Larsen, Peter LeWitt, Wolfgang Oertel, Niall Quinn, Kapil Sethi, Fabrizio Stocchi, Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment, Movement Disorders, 2005, 20, 6
  22. 22
    Nicolás Cuenca, María-Trinidad Herrero, Antonia Angulo, Emilio de Juan, Gema C. Martínez-Navarrete, Salvador López, Carlos Barcia, José Martín-Nieto, Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson's disease, Journal of Comparative Neurology, 2005, 493, 2
  23. 23
    Stéphane Thobois, Florence Delamarre-Damier, Pascal Derkinderen, Treatment of motor dysfunction in Parkinson's disease: an overview, Clinical Neurology and Neurosurgery, 2005, 107, 4, 269

    CrossRef

  24. 24
    Cheryl H. Waters, Kapil D. Sethi, Robert A. Hauser, Eric Molho, John M. Bertoni, Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study, Movement Disorders, 2004, 19, 4
  25. 25
    A. Albanese, C. Colosimo, Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists, Acta Neurologica Scandinavica, 2003, 107, 5
  26. 26
    Carlo Colosimo, Alessandra Craus, Noradrenergic Drugs for Levodopa-Induced Dyskinesia, Clinical Neuropharmacology, 2003, 26, 6, 299

    CrossRef

  27. 27
    I. Rektorová, I. Rektor, M. Bareš, V. Dostál, E. Ehler, Z. Fanfrdlová, J. Fiedler, H. Klajblová, P. Kulišt’ák, P. Ressner, J. Svátová, K. Urbánek, J. Velísková, Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study, European Journal of Neurology, 2003, 10, 4
  28. 28
    Tim Ibbotson, Karen L. Goa, Management of Parkinson??s Disease, Disease Management & Health Outcomes, 2002, 10, 10, 643

    CrossRef

  29. 29
    Richard C. Dodel, Karin Berger, Wolfgang H. Oertel, Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson??s Disease, PharmacoEconomics, 2001, 19, 10, 1013

    CrossRef

  30. 30
    Michael Schachter, 2001,

    CrossRef

  31. 31
    D. B. Olsen, A. R. Langkilde, H. Schmalbruch, J. Vissing, Diagnostic challenges in combined multiple sclerosis and centronuclear myopathy, European Journal of Neurology, 2000, 7, 5
  32. 32
    C. Colosimo, Disseminating information about new therapies for Parkinson's disease: misunderstanding or misconduct?, European Journal of Neurology, 2000, 7, 6
  33. 33
    Kenichi Kashihara, Yasuhiro Manabe, Yoshihiko Shiro, Hitoshi Warita, Koji Abe, Effects of repeated methyl levodopa administration on apomorphine sensitivity of rotational behavior and striatal Fos expression of rats with unilateral 6-OHDA lesions, Neuroscience Research, 2000, 38, 3, 273

    CrossRef

  34. 34
    José A. Obeso, C. Warren Olanow, John G. Nutt, Levodopa motor complications in Parkinson's disease, Trends in Neurosciences, 2000, 23, S2

    CrossRef